Tresalis Acquires Vyrao

Nivora Group Acquires AAVRANI

April 15, 2026

Consumer Products

AAVRANI, a prestige beauty brand known for Ayurvedic-inspired, clinically validated formulations, has been acquired by Nivora Group, a consumer private equity firm. Financial terms were not disclosed, and the deal is expected to support scaling distribution across the United States and select international markets.

Vividion Therapeutics Acquires Tavros Therapeutics

January 12, 2025

Biotechnology

Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.

LIAN Group Launches Vitaura and Acquires Medicina Estetica Zazzaron

January 9, 2025

Healthcare Services

LIAN Group has launched Vitaura, a buy-and-build consolidation platform for aesthetic medicine, surgery and longevity clinics in Italy, and announced Vitaura's first acquisition of Medicina Estetica Zazzaron (two locations in Veneto). The platform will retain clinical autonomy for acquired clinics, with Dr. Michela Zazzaron remaining in charge of the clinic; LIAN plans additional acquisitions (two near-term deals plus eight more over 36 months) to expand Vitaura nationwide.

Viking Global Investors Acquires Majority Stake in Voyado

December 3, 2024

Cloud & SaaS

Affiliates of Viking Global Investors have acquired a majority stake in Voyado, a Swedish retail-focused customer experience SaaS platform, in a deal intended to accelerate product development and expand Voyado's presence in the UK. Voyado has grown rapidly (32% average annual growth since 2022), is profitable, and was valued at SEK 3.5 billion (~£270 million) at the time of the transaction.

Nevro Corp. Acquires Vyrsa Technologies

November 30, 2023

Medical Devices

Nevro Corp. acquired Vyrsa Technologies, a privately held medical technology company focused on minimally invasive sacroiliac (SI) joint fusion devices, in a deal that closed November 30, 2023. Nevro paid $40 million at closing and may pay up to an additional $35 million in cash or stock tied to development and sales milestones; the company said Vyrsa will broaden its product portfolio and is projected to be accretive in 2024.

Certara Acquires Vyasa Analytics

January 4, 2023

AI & Machine Learning

Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.